The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Abstract
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding. BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and cured 70 percent of mice bearing extensive metastases of a human lung carcinoma. Also, BR96-DOX cured 94 percent of athymic rats with subcutaneous human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793
Carter, S. K. (1975) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/55.6.1265 · Cited by 453
Redesigning Nature's Poisons to Create Anti-Tumor Reagents
Vitetta, E. S., Fulton, R. J., May, R. D., Till, M., & Uhr, J. W. (1987) · Science · doi:10.1126/science.3317828 · Cited by 326
Sakamoto, S., Watanabe, T., Tokumaru, T., et al. (1989) · PubMed · Cited by 209
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M., Brown, A. N. F., Watson, G., Knyba, R. E., Wawrzynczak, E. J., & Blakey, D. C. (1987) · PubMed · Cited by 204
Kaneko, T., Willner, D., Monkovic, I., Knipe, J. O., Braslawsky, G. R., Greenfield, R. S., & Vyas, D. M. (1991) · Bioconjugate Chemistry · doi:10.1021/bc00009a001 · Cited by 163
Self-citationYang, H. M., & Reisfeld, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1189 · Cited by 153
Kulkarni, P. N., Blair, A. H., & Ti, G. (1981) · PubMed · Cited by 93
Mouse monoclonal antibody F-3 recognizes the difucosyl type-2 blood group structure
Lloyd, K. O., Larson, G., Str�mberg, N., Thurin, J., & Karlsson, K. (1983) · Immunogenetics · doi:10.1007/bf00696877 · Cited by 87
Pour, P. M., Tempero, M., Takasaki, H., Uchida, E., Takiyama, Y., Burnett, D. A., & Steplewski, Z. (1988) · PubMed · Cited by 82
Dillman, R. O., Johnson, D. E., Shawler, D. L., & Koziol, J. (1988) · PubMed · Cited by 77
Systemic immunotoxin therapy of cancer: advances and prospects
Wawrzynczak, E. J. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.374 · Cited by 63
Fell, H. P., Yarnold, S., Hellström, I., Hellström, K. E., & Folger, K. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8507 · Cited by 61
Self-citationTrail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Greenfield, R. S., Griffiths-King, D., Zoeckler, M. E., & Braslawsky, G. R. (1992) · PubMed · Cited by 55
Self-citationEffect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats.
Worrell, N. R., Cumber, A. J., Parnell, G. D., Mirza, A., Forrester, J. A., & Ross, W. C. J. (1986) · PubMed · Cited by 46
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Metadata
- Authors
- Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E.
- Venue
- Science
- Published
- 1993-07-09
- Volume
- 261
- Issue
- 5118
- Pages
- 212-215
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2055642315
- Cited by
- 556
- References
- 16
- FWCI
- 47.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.